Skip to main content
OpenTrials
Completed

NCT Number: NCT02470026

Noradrenergic Activity, Cognition and Major Depressive Disorder

This study investigates influences of nordadrenergic activity on cognition in patients with major depression regarding influences of early life stress.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Charite University

Berlin, Germany

About this study

Stress plays a major role in the development and maintenance of major depression disorder. Indeed, various studies demonstrated maladaptive changes in physiological stress regulation systems of depressive patients, i.e. in the hypothalamus-pituitary-adrenal axis and the locus coeruleus-noradrenergic system. On a central level, changes of the locus coeruleus-noradrenergic system have been demonstrated.This seems to be the case especially in depressive patients with early life traumata. Comparable to the hypothalamus-pituitary-adrenal axis, the locus coeruleus-noradrenergic system influences not only the physiological stress response, but has also central influence with effects on cognitive functions. Indeed, noradrenergic effects on cognitive functions such as attention, learning and memory have been demonstrated in healthy individuals. Even though deficits in cognitive domains are core symptoms of major depression, the relationship of the noradrenergic system and cognitive processes has rarely been investigated so far.

In this project, the investigators will examine noradrenergic influences via administration of the alpha2-receptor blocker yohimbine on cognitive and emotionally relevant processes in depressive patients and controls. Additionally, the investigators will examine the influence of early life traumata on these relationships. Thus, the investigators will examine participants with and without major depression and with and without early life stress.

Results of this study will improve the understanding of cognitive dysfunctions associated with the noradrenergic system in patients with major depression.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • diagnosis of major depression
  • experience of early life trauma

Exclusion criteria

  • severe illness
  • Alzheimer´s
  • schizophrenia
  • bipolar disorder
  • control group: - diagnosis of major depression/ experience of early life trauma

Treatment and study plan

Yohimbine

Drug

single low dose treatment

Placebo

Drug

single control treatment

Primary outcomes

  1. behavioral responses in two different conditions of noradrenergic stimulation

    Time frame: 2,5 hrs

    reaction times and error scores (computer tasks)

  2. physiological responses in two different conditions of noradrenergic stimulation

    Time frame: 2,5 hrs

    physiological recordings, saliva samples

Sponsors and collaborators

Lead sponsor

Charite University, Berlin, Germany

Other

Registry information

Official study title

Influences on Noradrenergic Activity for Cognition in Patients With Major Depressive Disorder

Acronym: YohCog

Important dates

Study start
2014
Primary completion
2017
Study completion
2018
First posted
Jun 12, 2015
Registry last updated
May 23, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.